Physician profile
Warren Kemper
NPI 1770595035
$13,213.06
in general payments reported to CMS, 2019-2025
35 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $1,866 · 2021: $2,369 · 2022: $2,298 · 2023: $1,743 · 2024: $2,014 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,238.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,962.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,462.69 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $1,408.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,132.35 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $992.87 | 2019-2025 | Jardiance, Tradjenta, Ofev |
| Amarin Pharma, INC. | $599.24 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $595.18 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $566.78 | 2019-2025 | |
| Lilly USA, LLC | $530.17 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $516.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $486.75 | 2019-2022 | |
| Abbvie INC. | $428.79 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $428.42 | 2022 | |
| Esperion Therapeutics, INC. | $378.70 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $231.28 | 2020-2021 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Kemper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.